Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Jefferies Healthcare Conference 2024
21 slides from Bico Group Ab Class B's conference presentation, Nov 21, 2024
Slide 1: Jefferies Healthcare Conference
JEFFERIES HEALTHCARE CONFERENCE - NOVEMBER 21, 2024 MARIA FORSS, PRESIDENT & CEO 2025-01-20
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 3: Vision and Mission
Vision BICO enables and automates the life science lab of the future Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 3
Slide 4: BICO in Figures
BICO in Figures Founded in 2016 65+ SEK 2.2bn Global Presence Net Sales No of Markets FY 2023 North Europe America 34% (33) Asia 52% (42) 13% (20) 820+ 46,000+ Rest of Employees the world Installed Instruments 1% (5) 12 Share of sales per geography 12,000+ Q2 2023 vs Q2 2024 Publications Companies 4
Slide 5: Sales, Adjusted EBITDA and Cash Flow from Operating Activities
FY 2022, FY 2023 and R12M Q2 24: Sales, Adjusted EBITDA and Cash Flow from Operating Activities Total Sales Adjusted EBITDA Operational cash flow SEK m SEK m % SEK m 2500 250 20 2,269 250 2,250 2,121 218 217 18 200 178 2000 200 16 150 14 98 100 1500 150 12 50 126 FY 2022 9.7 9.6 10 0 FY 2023 R12M 10
Slide 6: Be the First-choice Lab Automation Partner and Provider of Selected Workflows
Be the First-choice Lab Automation Partner and Provider of Selected Workflows to Pharma and Biotech LIFE SCIENCE LAB AUTOMATION BIOPRINTING SOLUTIONS 6
Slide 7: BICO Offers Solutions in Molecular Biology, Drug Discovery and Synthetic Biology
BICO Offers Solutions Predominantly in Molecular Biology, Drug Discovery and Synthetic Biology BICO focuses on the first three life science value chain steps Life sciences Value chain Drug & Basic research & (Bio)- 1 2 diagnostic 3 4 Clinical use discovery production development Biotechnology BICO’s
Slide 8: BICO's Portfolio of Solutions Serves Selected Workflows
BICO’s Portfolio of Solutions Serves Selected Workflows Synthetic Fields Molecular biology Drug discovery biology Diagnostic Applications / Basic Transla-tional Diagnostic Target Hit Generation & Lead Optimi- Animal Clinical Biologics, Proteins, and Small Molecule Manu- Activities Research Research
Slide 9: Strong Customer Base and Relationships in Top Pharma
Strong Customer Base and Relationships in Top Pharma* Biotech Cellino DeepCure Scribe Therapeutics Cosmetics Metagenomi Diagnostics Estée Lauder Pharma & Arpeggio Invitae Charles River Biopharma Laboratories Novo Nordisk AstraZeneca Eli Lilly EMD Sereno Astellas Merck KGaA Pfizer BMS Roche J&J Food
Slide 10: BICO Address Needs Holistically Through End-to-End Workflows
BICO Address Needs Holistically Through End-to-End Workflows Field Molecular biology Drug Discovery SynBio Share of revenue Hit Biologics, Basic Diagnostic Target Lead Animal Clinical proteins, Activity generation & small Today Ambition research testing discovery optimization models trials lead iden
Slide 11: Key Trends for BICO
Key Trends for BICO – Growing demand – Growing adoption of in- for integrated and - Technologies for rapid vitro testing instead of automated workflows compound screening animal testing* in labs for higher and hit to lead generation – Regulatory compliant efficiency and - Increased focus on platform
Slide 12: Total and Serviceable Addressable Market
Total and Serviceable Addressable Market Global TAM (by market segment, 2023, USDbn) Global SAM (by 2023, USDbn) Potential market size, independently from BICO’s ability Market size based on customers BICO can serve with to reach and serve it existing business Total ~3bn, average CAGR: +12% In-vitro
Slide 13: Lab Automation Industry Evolving Significantly
Lab Automation Industry Evolving significantly • Market size valued around USD 5.5-6.8bn in 2023 • Growth rate indicated at CAGR 6.3-9.3% in 2023 to 2035 • Integrated automated solutions market we estimate to USD 1.1-1.3 bn and expected to continue to grow faster than the overall lab automation mark
Slide 14: Lab Automation and Selected Workflows are the Cornerstones in BICO's Offering
Lab Automation and Selected Workflows are the Cornerstones in BICO’s Offering Instruments Consumables Bioprinting Lab Automation and selected workflows Services Data, AI and software 14
Slide 15: Updated Strategy BICO 2.0 – Strong Commercial Focus
Updated Strategy BICO 2.0 – Strong Commercial Focus Drive Commercial Excellence Further develop Ensure Enable Provide Scientific Increase integrated Regulatory End-to-End Workflow recurring data, AI and SW Compliance Lab automation Solutions revenue solutions Readiness 15
Slide 16: The Problem / The BICO Solution
The Problem Discovering new drugs and marketable scientific innovations • Takes years of time The BICO Solution • Cost millions to billions of dollars • May be heavily regulated Accelerating scientific research through automation 16 16
Slide 17: Laboratory Automation: The Breadth of Solutions
Laboratory Automation: INTEGRATED The breadth of solutions FULLY- AUTOMATED AUTOMATED SEMI- AUTOMATED MANUAL Connecting equipment through Biosero's Green Button Go® Software 17 17
Slide 18: The Impact of Automation
The Impact of Automation Reduce downstream Increase existing Maximize productivity process and assay equipment capacity to develop of development scientists development by up biopharmaceutical and labs by a minimum to 75% manufacturing processes by of 200% 400% 18
Slide 19: BICO Leads the Way in Solving the Challenges in Life Science
BICO Leads the Way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency Speed • Reducing the time to find optimal candidates for treatment therapies Accuracy • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models
Slide 20: BICO Vision and Strategic Agenda
BICO Vision and Strategic Agenda BICO ENABLES AND AUTOMATES Vision THE LIFE SCIENCE LAB OF THE FUTURE Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech Enable end-to-end Further develop Ensure regulatory Provide scientific Increase Strategic
Slide 21: Slide 21